CLINICAL TRIALS PROFILE FOR ACTIVASE
✉ Email this page to a colleague
All Clinical Trials for ACTIVASE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00250991 ↗ | Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1/Phase 2 | 2003-07-01 | The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke. |
| NCT00250991 ↗ | Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial | Completed | University of Cincinnati | Phase 1/Phase 2 | 2003-07-01 | The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke. |
| NCT00265005 ↗ | Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants | Terminated | Genentech, Inc. | Phase 1 | 2005-06-01 | The purpose of this study is to determine if alteplase is effective in dissolving a clot in a catheter in a large vein (central venous line or PICC line) or artery in infants less than 6 months of age. |
| NCT00265005 ↗ | Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants | Terminated | University of Louisville | Phase 1 | 2005-06-01 | The purpose of this study is to determine if alteplase is effective in dissolving a clot in a catheter in a large vein (central venous line or PICC line) or artery in infants less than 6 months of age. |
| NCT00284739 ↗ | Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses | Completed | Genentech, Inc. | Phase 2 | 2006-02-01 | Intracavitary injection of low dose alteplase into loculated abdominopelvic abscesses will reduce the duration of percutaneous drainage and increase the proportion of successful drainages. |
| NCT00284739 ↗ | Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses | Completed | Kaiser Permanente | Phase 2 | 2006-02-01 | Intracavitary injection of low dose alteplase into loculated abdominopelvic abscesses will reduce the duration of percutaneous drainage and increase the proportion of successful drainages. |
| NCT00307580 ↗ | Cathflo Activase Pediatric Study | Completed | Genentech, Inc. | Phase 4 | 2002-04-01 | This was a Phase IV, open-label, single-arm, multicenter trial that was to be conducted at ~60 sites in the United States. Approximately 300 pediatric subjects with dysfunctional CVADs (including catheters with valves, multiple lumens, umbilical catheters, and implanted ports) were to be treated with up to two serially instilled doses of Cathflo Activase. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ACTIVASE
Condition Name
Clinical Trial Locations for ACTIVASE
Trials by Country
Clinical Trial Progress for ACTIVASE
Clinical Trial Phase
Clinical Trial Sponsors for ACTIVASE
Sponsor Name
